Back to Journals » ClinicoEconomics and Outcomes Research » Volume 7

Linezolid for the treatment of hospital-acquired pneumonia in a Chinese tertiary hospital

Authors Lesher B, Liu Z, Chen Y, Gao X

Received 29 May 2015

Accepted for publication 3 June 2015

Published 9 October 2015 Volume 2015:7 Pages 521—526

DOI https://doi.org/10.2147/CEOR.S89570

Checked for plagiarism Yes

Editor who approved publication: Dr Giorgio Colombo

Beth A Lesher,1 Zhengyin Liu,2 Yixi Chen,3 Xin Gao1

1Pharmerit International, Bethesda, MD, USA; 2Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 3Pfizer Investment Co, Ltd, Beijing, People’s Republic of China

We read with interest the study published by Song et al describing their retrospective analysis of the clinical response and hospital costs associated with the empiric use of vancomycin or linezolid therapy in patients with hospital-acquired pneumonia (HAP) in the People’s Republic of China.1 Results from matched comparisons showed similar clinical response (30.0% vs 31.7%; P=0.847) and treatment failure rates (55.0% vs 45.0%; P=0.289) but a significantly lower in-hospital mortality rate (3.3 vs 18.3%; P=0.013) for vancomycin-treated patients compared to linezolid-treated patients. Treatment failure rates (odds ratio [OR], 1.139; P=0.308) and risk of in-hospital mortality were comparable (OR, 0.186; P=0.055) between vancomycin- and linezolid-treated patients following further adjustment for an imbalance in variables between the matched treatment groups. Reported total hospital costs were not significantly different between vancomycin- (RMB 113,160) and linezolid (RMB 133,825)-treated patients (P=0.076).

View original paper by Song et al

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]